(Total Views: 630)
Posted On: 12/01/2020 6:51:40 PM
Post# of 145247
Testing a wide variety of parameters in clinical trials should be made mandatory by the FDA. Determining the downstream of the mechanism of action is a safety issue.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)